Form 8-K

8-K — SANGAMO THERAPEUTICS, INC

Accession: 0001193125-26-434171

Filed: 2026-10-27

Period: 2026-10-23

CIK: 0001001233

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — d179328d8k.htm (Primary)

EX-99.1 (d179328dex991.htm)

EX-99.2 (d179328dex992.htm)

EX-99.3 (d179328dex993.htm)

GRAPHIC (g179328dsp015.jpg)

GRAPHIC (g179328dsp016.jpg)

GRAPHIC (g179328dsp017.jpg)

GRAPHIC (g179328dsp042.jpg)

GRAPHIC (g179328dsp043.jpg)

GRAPHIC (g179328dsp06.jpg)

GRAPHIC (g179328dsp06a.jpg)

GRAPHIC (g179328dsp06b.jpg)

GRAPHIC (g179328dsp072.jpg)

GRAPHIC (g179328dsp44.jpg)

GRAPHIC (g179328dsp70.jpg)

GRAPHIC (g179328dsp71.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d179328d8k.htm · Sequence: 1

8-K

NONE 0001001233 false 0001001233 2026-10-23 2026-10-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2026

SANGAMO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

000-30171

68-0359556

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

ID Number)

501 Canal Blvd., Richmond, California 94804

(Address of principal executive offices) (Zip Code)

(510) 970-6000

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common stock, par value $0.01 per share

SGMOQ

N/A (OTC Expert Market)*

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Following a determination by the Nasdaq Stock Market LLC (“Nasdaq”) to delist the common stock of Sangamo Therapeutics, Inc. (the “Company”), the Company’s common stock was suspended from trading on Nasdaq on May 5, 2026 and currently trades on the OTC Expert Market on an unsolicited quotes only basis. On October 7, 2026, Nasdaq filed a Form 25 with the Securities and Exchange Commission to delist and deregister the Company’s common stock under Section 12(b) of the Exchange Act. The delisting became effective October 17, 2026.

Item 7.01

Regulation FD Disclosure.

As previously announced, on June 23, 2026, Sangamo Therapeutics, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the Company (the “Chapter 11 Case”). The case number is 26-10989 and the case is styled as In re Sangamo Therapeutics, Inc.

On October 23, 2026, the Company filed with the Bankruptcy Court (i) an amended monthly operating report for each of the periods from (a) July 1, 2026 to July 31, 2026 (the “Amended July MOR”), originally filed with the Securities and Exchange Commission (the “Commission”) on a Current Report on Form 8-K on September 8, 2026 and (b) August 1, 2026 to August 31, 2026 (the “Amended August MOR”), originally filed with the Commission on a Current Report on Form 8-K on October 15, 2026 and (ii) its monthly operating report for the period beginning September 1, 2026 and ended September 30, 2026 (the “September MOR,” together with each of the Amended July MOR and Amended August MOR, the “MORs”).

The information set forth in Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information required to be disclosed solely by Regulation FD. The MORs are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3. The MORs and additional information regarding the Chapter 11 Case is available at https://www.veritaglobal.net/SangamoTherapeutics. The documents and other information on this website are not part of this Current Report on Form 8-K and shall not be incorporated by reference.

The information contained in this Item 7.01 and in Exhibit 99.1 is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Cautionary Statement Regarding the MORs

The Company cautions investors and potential investors not to place undue reliance upon the information contained in the MORs, which were not prepared for the purpose of providing the basis for an investment decision relating to any of the securities of the Company. The MORs are limited in scope, cover a limited time period and have been prepared solely for the purpose of complying with the reporting requirements of the Bankruptcy Court. The MORs are not audited or reviewed by independent accountants, were not prepared in accordance with generally accepted accounting principles in the United States, are in a format prescribed by applicable bankruptcy laws or rules, and are subject to future adjustment and reconciliation. The MORs also contain information for periods shorter than and otherwise different from those contained in the Company’s reports required to be filed pursuant to the Exchange Act. There can be no assurance that, from the perspective of an investor or potential investor in the Company’s securities, the MORs are complete. Results set forth in the MORs should not be viewed as indicative of future results.

Cautionary Language Regarding Trading in the Company’s Common Stock

The Company’s stockholders are cautioned that trading in the Company’s common stock during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks. The Company’s common stock has been suspended from trading on the Nasdaq Capital Market (“Nasdaq”), and following the filing of a Form 25 by Nasdaq on October 7, 2026, was delisted effective October 17, 2026. The Company’s common stock is currently trading on the OTC Expert Market on an unsolicited quotes only basis, and trading prices for the Company’s common stock may bear little or no relationship to the actual recovery, if any, by holders thereof in the Company’s Chapter 11 Case. Accordingly, the Company urges extreme caution with respect to existing and future investments in its common stock.

Cautionary Language Regarding Forward-Looking Statements

This Current Report on Form 8-K contains certain forward-looking statements that reflect, when made, the Company’s current views with respect to current events and financial performance. These forward-looking statements are within the meaning of Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding process and potential outcomes of the Company’s Chapter 11 Case and/or statements preceded by, followed by or that include the words “intends,” “expects,” “estimates,” “plans,” or similar expressions. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, beliefs and expectations, there can be no assurance that its expectations will be achieved. Except as otherwise may be required by law, the Company undertakes no obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances, or changes in expectations after the date of this Current Report on Form 8-K.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Description of Document

99.1

Sangamo Therapeutics, Inc. Amended Monthly Operating Report for the period ended July 31, 2026.

99.2

Sangamo Therapeutics, Inc. Amended Monthly Operating Report for the period ended August 31, 2026.

99.3

Sangamo Therapeutics, Inc. Monthly Operating Report for the period ended September 30, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SANGAMO THERAPEUTICS, INC.

Date: October 27, 2026

By:

/s/ SCOTT B. WILLOUGHBY

Scott B. Willoughby

Chief Legal Officer and Corporate Secretary

EX-99.1

Filename: d179328dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

UNITED STATES BANKRUPTCY COURT

DISTRICT OF DELAWARE

In Re. SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Debtor(s)

☐ Jointly Administered

Amended Monthly Operating Report

Chapter 11

Reporting Period Ended: 07/31/2026

Petition Date:

06/23/2026

Months Pending: 1

Industry Classification:

Reporting Method:

Accrual Basis

Cash Basis

Debtor’s Full-Time Employees (current):

Debtor’s Full-Time Employees (as of date of order for relief):

Supporting Documentation (check all that are

attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis

for each debtor)

☒

Statement of cash receipts and disbursements

☒

Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit

☒

Statement of operations (profit or loss statement)

☐

Accounts receivable aging

☐

Postpetition liabilities aging

☐

Statement of capital assets

☐

Schedule of payments to professionals

☒

Schedule of payments to insiders

☒

All bank statements and bank reconciliations for the reporting period

☐

Description of the assets sold or transferred and the terms of the sale or transfer

/s/ Nikunj Jain

Nikunj Jain

Signature of Responsible Party

Printed Name of Responsible Party

10/23/2026

Date

501 Canal Blvd., Suite A100 Richmond, CA 94804

Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. §1320.4(a)(2) applies.

UST Form 11-MOR (12/01/2021)

Docket No. 537

Filed: 10/23/26

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Part 1: Cash Receipts and Disbursements

Current Month

Cumulative

Cash balance beginning of month

14,382,244

Total receipts (net of transfers between accounts)

18,058,990

28,562,062

Total disbursements (net of transfers between accounts)

15,534,279

16,512,210

Cash balance end of month (a+b-c)

16,906,955

Disbursements made by third party for the benefit of the estate

Total disbursements for quarterly fee calculation (c+e)

15,534,279

16,512,210

Part 2: Asset and Liability Status

(Not generally applicable to Individual Debtors. See Instructions.)

Current Month

Accounts receivable (total net of allowance)

500,160

Accounts receivable over 90 days outstanding (net of allowance)

90,355

Inventory (Book

Market

Other

(attach explanation))

Total current assets

20,386,655

Total assets

155,117,944

Postpetition payables (excluding taxes)

18,768,593

Postpetition payables past due (excluding taxes)

366,473

Postpetition taxes payable

269,455

Postpetition taxes past due

Total postpetition debt (f+h)

19,038,048

Prepetition secured debt

Prepetition priority debt

32,543

Prepetition unsecured debt

78,061,802

Total liabilities (debt) (j+k+l+m)

97,132,393

Ending equity/net worth (e-n)

57,985,551

Part 3: Assets Sold or Transferred

Current Month

Cumulative

Total cash sales price for assets sold/transferred outside the ordinary course of business

Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business

Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)

Part 4: Income Statement (Statement of Operations)

(Not generally applicable to Individual Debtors. See Instructions.)

Current Month

Cumulative

Gross income/sales (net of returns and allowances)

720,000

Cost of goods sold (inclusive of depreciation, if applicable)

Gross profit (a-b)

720,000

Selling expenses

General and administrative expenses

3,764,872

Other expenses

3,231,570

Depreciation and/or amortization (not included in 4b)

216,290

Interest

105,000

Taxes (local, state, and federal)

Reorganization items

4,244,225

Profit (loss)

-11,165,298

-14,920,356

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Part 5: Professional Fees and Expenses

Approved

Current Month

Approved

Cumulative

Paid Current

Month

Paid

Cumulative

Debtor’s professional fees & expenses (bankruptcy) Aggregate Total

Itemized Breakdown by Firm

Firm Name

Role

iii

vii

viii

xii

xiii

xiv

xvi

xvii

xviii

xix

xxi

xxii

xxiii

xxiv

xxv

xxvi

xxvii

xxviii

xxix

xxx

xxxi

xxxii

xxxiii

xxxiv

xxxv

xxxvi

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

xxxvii

xxxviii

xxxix

xli

xlii

xliii

xliv

xlv

xlvi

xlvii

xlviii

xlix

lii

liii

liv

lvi

lvii

lviii

lix

lxi

lxii

lxiii

lxiv

lxv

lxvi

lxvii

lxviii

lxix

lxx

lxxi

lxxii

lxxiii

lxxiv

lxxv

lxxvi

lxxvii

lxxviii

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

lxxix

lxxx

lxxxi

lxxxii

lxxxiii

lxxxiv

lxxxv

lxxxvi

lxxxvii

lxxxviii

lxxxix

xci

xcii

xciii

xciv

xcv

xcvi

xcvii

xcviii

xcix

Approved

Current Month

Approved

Cumulative

Paid Current

Month

Paid

Cumulative

Debtor’s professional fees & expenses (nonbankruptcy) Aggregate Total

$348

Itemized Breakdown by Firm

Firm Name

Role

Rothwell, Figg, Ernst & Manbec

Special Counsel

$295

Daijogo & Pedersen, LLP

Special Counsel

$ 52

iii

vii

viii

xii

xiii

xiv

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

xvi

xvii

xviii

xix

xxi

xxii

xxiii

xxiv

xxv

xxvi

xxvii

xxviii

xxix

xxx

xxxi

xxxii

xxxiii

xxxiv

xxxv

xxxvi

xxxvii

xxxviii

xxxix

xli

xlii

xliii

xliv

xlv

xlvi

xlvii

xlviii

xlix

lii

liii

liv

lvi

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

lvii

lviii

lix

lxi

lxii

lxiii

lxiv

lxv

lxvi

lxvii

lxviii

lxix

lxx

lxxi

lxxii

lxxiii

lxxiv

lxxv

lxxvi

lxxvii

lxxviii

lxxix

lxxx

lxxxi

lxxxii

lxxxiii

lxxxiv

lxxxv

lxxxvi

lxxxvii

lxxxviii

lxxxix

xci

xcii

xciii

xciv

xcv

xcvi

xcvii

xcviii

xcix

c. All professional fees and expenses (debtor & committees)

$ 0

$348

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Part 6: Postpetition Taxes

Current Month

Cumulative

a. Postpetition income taxes accrued (local, state, and federal)

b. Postpetition income taxes paid (local, state, and federal)

c. Postpetition employer payroll taxes accrued

226,736

282,175

d. Postpetition employer payroll taxes paid

421,834

e. Postpetition property taxes paid

f. Postpetition other taxes accrued (local, state, and federal)

39,582

57,404

g. Postpetition other taxes paid (local, state, and federal)

Part 7: Questionnaire - During this reporting period:

a. Were any payments made on prepetition debt? (if yes, see

Instructions)

Yes

b. Were any payments made outside the ordinary course of business without court

approval? (if yes, see Instructions)

Yes

c. Were any payments made to or on behalf of insiders?

Yes

d. Are you current on postpetition tax return filings?

Yes

e. Are you current on postpetition estimated tax payments?

Yes

f. Were all trust fund taxes remitted on a current basis?

Yes

g. Was there any postpetition borrowing, other than trade credit? (if yes, see

Instructions)

Yes

h. Were all payments made to or on behalf of professionals approved by the

court?

Yes

N/A

i. Do you have: Worker’s compensation insurance?

Yes

If yes, are your premiums current?

Yes

N/A

(if no, see Instructions)

Casualty/property insurance?

Yes

If yes, are your premiums current?

Yes

N/A

(if no, see Instructions)

General liability insurance?

Yes

If yes, are your premiums current?

Yes

N/A

(if no, see Instructions)

j. Has a plan of reorganization been filed with the court?

Yes

k. Has a disclosure statement been filed with the court?

Yes

1. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C.

§ 1930?

Yes

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Part 8: Individual Chapter 11 Debtors (Only)

a. Gross income (receipts) from salary and wages

$ 0

b. Gross income (receipts) from self-employment

$ 0

c. Gross income from all other sources

$ 0

d. Total income in the reporting period (a+b+c)

$ 0

e. Payroll deductions

$ 0

f. Self-employment related expenses

$ 0

g. Living expenses

$ 0

h. All other expenses

$ 0

i. Total expenses in the reporting period (e+f+g+h)

$ 0

j. Difference between total income and total expenses (d-i)

$ 0

k. List the total amount of all postpetition debts that are past due

$ 0

l. Are you required to pay any Domestic Support Obligations as defined by 11

U.S.C § 101(14A)?

Yes

m. If yes, have you made all Domestic Support Obligation payments?

Yes

N/A

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106,

and 1107. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6). The United States Trustee will also use this information to evaluate a chapter 11 debtor’s progress through

the bankruptcy system, including the likelihood of a plan of reorganization being confirmed and whether the case is being prosecuted in good faith. This information may be disclosed to a bankruptcy trustee or examiner when the information is needed

to perform the trustee’s or examiner’s duties or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures

may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee’s systems of records notice,

UST-001, “Bankruptcy Case Files and Associated Records.” See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link:

http://www.justice.gov/ust/ eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I

have been authorized to sign this report on behalf of the estate.

/s/ Nikunj Jain

Nikunj Jain

Signature of Responsible Party

Printed Name of Responsible Party

Interim Chief Financial Officer

10/23/2026

Title

Date

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

PageOnePartOne PageOnePartTwo PageTwoPartOne PageTwoPartTwo

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Bankruptcy1to50 Bankruptcy51to100 NonBankruptcy1to50 NonBankruptcy51to100

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

PageThree PageFour

UST Form 11-MOR (12/01/2021)

IN THE UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT DELAWARE

)

In re:

)

Chapter 11

)

SANGAMO THERAPEUTICS, INC.

)

Case No. 26-10989 (CTG)

)

Debtor.1

)

GLOBAL NOTES AND STATEMENT OF LIMITATIONS, METHODOLOGY, AND DISCLAIMERS REGARDING THE DEBTOR’S

AMENDED2 MONTHLY OPERATING REPORT

On June 23, 2026 (the “Petition Date”), Sangamo Therapeutics, Inc. (the “Debtor”) commenced the

above-captioned chapter 11 case by filing a voluntary petition for relief under chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) with the United States Bankruptcy Court for the District of Delaware (the

“Court”). The Debtor is authorized to operate its business as a debtor-in-possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code.

General Methodology

The Debtor is filing its monthly operating report (the “MOR”) for the period from July 1, 2026 through July 31, 2026

(the “Reporting Period”) for purposes of complying with the monthly reporting requirements applicable in the Debtor’s chapter 11 case. The MOR is unaudited and has not been prepared in accordance with accounting principles

generally accepted in the United States of America (“U.S. GAAP”) and does not include all of the information and footnotes required by U.S. GAAP. The MOR is not intended to reconcile to any financial statements otherwise prepared

or distributed by the Debtor. The MOR should not be relied upon by any persons for information relating to current or future financial condition, events, or performance of the Debtor or its affiliates, as the results of operations contained herein

are not necessarily indicative of results which may be expected from any other period or for the full year and may not necessarily reflect the results of operations, financial position, and schedule of receipts and disbursements in the future.

The Debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc.

(9556). The Debtor’s mailing address is 501 Canal Blvd., Ste A100, Richmond, CA 94804.

This amended monthly operating report amends the July monthly operating report filed at Docket No. 427 to

add information regarding payments inadvertently made to ordinary course professionals, as set forth in part 5(b) of the monthly operating report form and the attached attestation titled “Part 7(b) and 7(h) Payments Without Court

Approval.”

Basis for Presentation

In preparing the MOR, the Debtor relied on financial information from its books and records at the time of such preparation. The financial

information contained in the MOR is derived from the Debtor’s books and records without, among other things, all adjustments or reclassification that may be necessary or typical to accord with U.S. GAAP.

This information has not been subjected to procedures that would typically be applied to financial information presented in accordance with

U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtor believes that the financial information presented in the MOR could be subject to change, including material change.

Although the Debtor made efforts to ensure the accuracy and completeness of the MOR, given the complexity of the Debtor’s business,

inadvertent errors or omissions may occur. Accordingly, the Debtor hereby reserves all rights to dispute the nature, validity, status, enforceability, or executory nature of any claim amount, agreement, representation, or other statement set forth

in the MOR. Further, the Debtor reserves the right to amend or supplement the MOR, if necessary, but shall be under no obligation to do so.

Moreover, given, among other things, the uncertainty surrounding the valuation and ownership of certain assets and the valuation and nature of

certain liabilities, to the extent the Debtor shows more assets than liabilities, it is not an admission that the Debtor was solvent as of the Petition Date or at any time prior to the Petition Date. Likewise, to the extent the Debtor shows more

liabilities than assets, it is not an admission that the Debtor was insolvent at the Petition Date or any time prior to the Petition Date.

For the reasons discussed above, there can be no assurance that the financial information presented in the MOR is complete, and readers are

strongly cautioned not to place undue reliance on the MOR.

Each signatory to the MOR has necessarily relied upon the efforts, statements,

advice, and representations of personnel of the Debtor and the Debtor’s advisors and professionals. Each signatory has not (and could not have) personally verified the accuracy of each such statement, representation, and answer contained in

the MOR.

Reporting Period

Unless otherwise noted herein, the MOR generally reflects the Debtor’s books and records for the applicable Reporting Period. Unless

otherwise noted herein, no adjustments have been made for activity occurring after the close of the Reporting Period.

Accuracy

The financial information disclosed in the MOR was not prepared in accordance with federal or state securities laws or other

applicable non-bankruptcy law or in lieu of complying with any periodic reporting requirements thereunder. Persons and entities trading in or otherwise purchasing, selling, or transferring the claims against

or equity interests in the Debtor should evaluate the financial information in light of the purposes for which it was prepared. The Debtor and its advisors are not liable for and undertake no responsibility to indicate variations from securities

laws in the MOR or for any evaluations of the Debtor, including of their financial condition, based on this financial information or any other information.

Debtor in Possession Financing

On June 25, 2026, the Court entered the Interim Order (A) Authorizing the Debtor to Obtain Postpetition Financing,

(B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief

[Docket No. 63] (the “Initial Interim DIP Order”) authorizing the Debtor to enter into a senior secured superpriority debtor-in-possession

term loan facility (the “Initial DIP Facility”). Prior to the Reporting Period, the Debtor drew $10,500,000 under the Initial DIP Facility. Please refer to the motion [Docket No. 10] seeking entry of the Initial Interim DIP

Order for additional information regarding the Initial DIP Facility.

On July 23, 2026, the Court entered the Interim Order

(A) Authorizing the Debtor to Obtain Replacement Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay,

(D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 176] (the “Replacement Interim DIP Order”), which among other things, authorized the Debtor to enter into a senior

secured superpriority debtor-in-possession term loan facility (the “Replacement DIP Facility”) to replace the Initial DIP Facility. During the

Reporting Period, the Debtor incurred $18 million in DIP Obligations (as defined in the Replacement DIP Order) under the Replacement DIP Order, $11,432,958 of which was paid by the Debtor or on the Debtor’s behalf to satisfy all

outstanding obligations arising under the Initial DIP Facility, including all fees. Please refer to the motion [Docket No. 161] seeking entry of the Replacement Interim DIP Order for additional information regarding the Replacement DIP

Facility.

Payment of Prepetition Claims Pursuant to First Day Orders

Pursuant to certain interim orders of the Court entered on or about June 24, 2026 and final orders of the Court entered on or about

July 21, 2026 (the “First Day Orders”), the Debtor is authorized (but not directed) to pay, among other things, certain prepetition claims of employees and taxing authorities. Accordingly, these liabilities may have been or

may be satisfied in accordance with such First Day Orders. To the extent any payments were made on account of prepetition claims following the Petition Date pursuant to the authority granted to the Debtor under the First Day Orders, such payments

have been included in the MOR (subject to the notes and statements and limitations provided herein).

Reservation of Rights

The Debtor reserves all rights to amend or supplement the MOR in all respects, as may be necessary or appropriate. Nothing

contained in the MOR shall constitute a waiver of any of the Debtor’s rights or an admission with respect to any claim against the Debtor or otherwise in connection with this chapter 11 case

Specific MOR Disclosures

Part

1: Cash Receipts and Disbursements

Pursuant to the Initial Interim DIP Order and Replacement Interim DIP Order (together the “Interim DIP

Orders”), fees and expenses of estate professionals were placed into the Professional Fees Account (as defined in the Interim DIP Orders) maintained by the Debtor. The transfer of such funds to the Professional Fee Account were treated as

a transfer between Debtor accounts, and, therefore, were not treated as a distribution in Part 1(c). Professional fees will be treated as a disbursement in the reporting period in which they are paid to the applicable professionals.

Similarly, pursuant to the interim and final orders approving, among other things, the Debtor’s

proposed form of adequate assurance of payment to utility companies [Docket No. 56 & 142] (the “Utilities Orders”), the Debtor deposited funds into the Utility Deposit Account (as defined in the Utilities Orders)

maintained by the Debtor prior to the Reporting Period. The funds in such account will be treated as disbursements only if they are ultimately paid to a third party.

Notes to Part 2: Asset and Liability Status

Unless

otherwise noted, all asset and liability information included in the MOR reflects net book value, which may differ from current market value. As set forth above, this information has not been subjected to procedures that would typically be applied

to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were applied, the Debtor believes that the financial information presented in the MOR could be subject to

change, including material change. Asset and liability information includes intercompany claims and other assets and liabilities which may not be settled in cash.

The Debtor continues to pay postpetition invoices on account of postpetition goods provided and services rendered in the ordinary course of business.

Given the Petition Date did not occur at month end, certain prepetition and postpetition liability balances are estimated. The Debtor has sought to assign

liabilities to the prepetition and postpetition periods based on the information available as of and at the time the MOR was prepared. As additional information becomes available, the allocation of liabilities between prepetition and postpetition

periods may change. The Debtor reserves the right to amend the balances as it deems appropriate and any such amendments will be reflected in future MORs

The amounts listed as “Prepetition Secured Debt,” “Prepetition Priority Debt” and “Prepetition Unsecured Debt” are

preliminary and are subject to ongoing review and reconciliation by the Debtor. All amounts and classifications are subject to material adjustments.

Regarding Part 2c, the Debtor does not hold inventory; therefore, no inventory valuation method is applicable.

Notes to Part 6: Postpetition Taxes

Regarding Part

6c and 6d, postpetition employer payroll taxes accrued and paid include both the employer and employee portions of payroll taxes.

Notes to

Part 7: Questionnaire

Regarding Part 7a, and as mentioned above, the Debtor is authorized to pay certain prepetition claims and obligations

pursuant to the First Day Orders.

Regarding Part 7g, the Debtor incurred $18 million in DIP Obligations under the Replacement DIP

Facility during the Reporting Period. The DIP Obligations were paid by the Debtor or on the Debtor’s behalf to pay all outstanding obligations under the Initial DIP Facility and to fund the Debtor’s business operations and its chapter 11

case.

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.

Case No: 26-10989

Schedule of Post-Petition Borrowing Activity

Reporting Period: July 1, 2026 – July 31, 2026

The Debtor hereby submits this attestation regarding postpetition borrowing during the period of July 1, 2026 through July 31, 2026.

In accordance with the Interim Order (A) Authorizing the Debtor to Obtain Replacement Postpetition Financing, (B) Granting Liens

and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 176]

(the “Replacement Interim DIP Order”), the Debtor incurred $18 million in DIP Obligations under the Replacement DIP Facility (each as defined in the Replacement Interim DIP Order) during the Reporting Period.

/s/ Nikunj Jain

October 23, 2026

Signature of Authorized Individual

Date

Nikunj Jain

Interim Chief Financial Officer

Printed Name of Authorized Individual

Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.

Case No: 26-10989

Schedule of Payments on Prepetition Debt

Reporting Period: July 1, 2026 – July 31, 2026

All payments made by the Debtor during the Reporting Period (and included in the disbursements reported in this MOR) were authorized under various final

orders granted by the Court, which authorized the Debtor’s various motions that were filed following the commencement of the chapter 11 case.

/s/ Nikunj Jain

October 23, 2026

Signature of Authorized Individual

Date

Nikunj Jain

Interim Chief Financial Officer

Printed Name of Authorized Individual

Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.

Case No: 26-10989

Part 7(b) and 7(h) Payments Without Court Approval

Reporting Period: July 1, 2026 – July 31, 2026

Payments made by the Debtor to Rothwell, Figg, Ernst & Manbeck, P.C. and Daijogo & Pedersen, LLP were inadvertently made prior to such

firm’s retention as ordinary course professionals in accordance with the OCP Order [Docket No. 202].

/s/ Nikunj Jain

October 23, 2026

Signature of Authorized Individual

Date

Nikunj Jain

Interim Chief Financial Officer

Printed Name of Authorized Individual

Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.

Case No: 26-10989

Schedule of Payments to Insiders

Reporting Period: July 1, 2026 – July 31, 2026

The Debtor hereby submits this attestation regarding payments to insiders during the period of July 1, 2026 through July 31, 2026.

With respect to insiders, all cash payments made were on account of ordinary course salaries and authorized travel and expense reimbursements.

No non-cash transfers were made during this reporting period.

/s/ Nikunj Jain

October 23, 2026

Signature of Authorized Individual

Date

Nikunj Jain

Interim Chief Financial Officer

Printed Name of Authorized Individual

Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.

Case No: 26-10989

All bank statements and bank reconciliations for the reporting period

Reporting Period: July 1, 2026 – July 31, 2026

The Debtor hereby submits this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations, and

journal entries.

The Debtor’s standard practice is to ensure that bank reconciliations are completed as part of the month end close each reporting

period. I attest that each of the Debtor’s bank accounts has been reconciled in accordance with their standard practices.

/s/ Nikunj Jain

October 23, 2026

Signature of Authorized Individual

Date

Nikunj Jain

Interim Chief Financial Officer

Printed Name of Authorized Individual

Title of Authorized Individual

Sangamo Therapeutics Inc.

MOR #2 - Statement of cash receipts and

disbursements

Units (i.e. $ in 000s)

07/01/2026 -

07/31/2026

Receipts

DIP Draw

18,000

Total Receipts

18,059

Operational Disbursements

Payroll & Benefits

1,747

Rent & Facilities

1,348

Program Costs

319

International Operations

416

Other Operating Disbursements

271

Total Operational Disbursements

4,101

Restructuring Disbursements

Professional Fees

—

US Trustee Fees

—

DIP Interest & Fees

933

DIP Repayments

10,500

Total Restructuring Disbursements

11,433

Net Cash Flow

2,525

Cash, cash equivalents, and restricted cash, beginning of period

14,382

Cash, cash equivalents, and restricted cash, end of period

16,907

1 of 4

Sangamo Therapeutics Inc.

MOR #2 - Balance sheet

Units (i.e. $ in 000s)

As of

6/30/2026

7/31/2026

Assets

Cash, Cash Equivalents and Restricted Cash

14,382

16,910

Accounts Receivables

500

Other Current Assets

3,303

2,977

Inventory

—

I/C Receivables - Current

—

Total Current Assets

18,186

20,387

Property, Plant & Equipment (Net)

9,644

9,430

Right of Use Assets

2,747

2,694

Other Non-Current Assets

779

Investments in Subsidiaries

115,762

I/C Receivables - Non-Current

5,970

6,067

Total Non-Current Assets

134,902

134,731

Total Assets

153,087

155,118

Liabilities and Stockholders’ Equity

A/P and Accrued Liabilities

30,620

36,735

Compensation and Benefits Liabilities

13,304

17,304

DIP Loan Payables

10,500

18,000

Other Current Liabilities1

9,001

8,713

I/C Payables - Current

42,651

42,687

Other Non-Current Liabilities1

23,678

23,240

I/C Payables - Non-Current

692

703

Non-Current Portion of Long-Term Debt

—

Total Liabilities

130,446

147,383

Stock

1,643,342

Retained Earnings

(1,564,836

)

(1,564,836

)

Other Equity

(30

)

(30

)

Net Income

(55,834

)

(70,741

)

Total Stockholders’ Equity

22,642

7,735

Total Liabilities and Stockholders’ Equity

153,087

155,118

Notes:

Includes Deferred Revenues and Lease Liabilities

2 of 4

Sangamo Therapeutics Inc.

MOR #2 - Statement of operations

(profit or loss statement)

Units (i.e. $ in 000s)

07/01/2026 -

07/31/2026

Total Revenue

720

COGS

—

Gross Profit

720

Personnel & Staffing Costs1

1,931

R&D Expenses2

3,184

Selling Expenses

—

General and Administrative Expenses

863

Facilities & OH Expenses1

972

I/C Expenses2

Other Expenses2

Interest Expense

105

Restructuring Expenses3

4,244

Depreciation and/or amortization

216

Total Operating Expenses

11,562

Unrealized FX (Gain)/Loss

336

Non-Operating (Income)/Expense

(12

)

Total Non-Operating (Income)/Expense

323

Net Profit/(Loss) for the Period

11,165

)

Notes:

Considered under “General and Administrative Expenses” for MOR

Considered under “Other Expenses” for MOR

Includes professional fees and DIP loan fees accruals

3 of 4

Sangamo Therapeutics Inc.

MOR #2 - Detailed explanations

Part 2 - Question C - Inventory

Sangamo does not hold

inventory; therefore, no inventory valuation method is applicable

Part 7 - Question G - Was there any postpetition borrowing, other than trade credit?

Detail

Date

Payee/Lender Name

Amount

DIP Replacement - Future Solutions Invenstment

7/24/2026

Future Solution Investments LLC

18,000,000

4 of 4

Miscellaneous:

26-10989-CTG Sangamo Therapeutics, Inc.

Type: bk

Chapter: 11 v

Office: 1 (Delaware)

Assets: y

Judge: CTG

Case Flag: CLMSAGNT, LeadSC, PlnDue, DsclsDue, STANDOrder, SealedDoc(s)

U.S. Bankruptcy Court

District of Delaware

Notice of

Electronic Filing

The following transaction was received from James McCauley entered on 10/23/2026 at 12:33 PM EDT and filed on 10/23/2026

Case Name:

Sangamo Therapeutics, Inc.

Case Number:

26- 10989-CTG

Document Number:

537

Docket Text:

Amended

Chapter 11 Monthly Operating Report for the Month Ending: 07/31/2026 (related document(s)[427]) Filed by Sangamo Therapeutics, Inc.. (McCauley, James)

The following document(s) are associated with this transaction:

Document description: Main Document

Original

filename: SGMO - July 2026 MOR [AMENDED]. pdf

Electronic document Stamp:

[STAMP bkecfStamp_ID=983460418 [Date=10/23/2026] [FileNumber=20049499-

0] [11 553d83764abea0bc846f63b121877f75bdf5cf7446f5ff90d993f070d73eec6a

4de2e06f9b7441c242c2714f7cd0e0554586255ef2836d209d30badcd0adee]]

26-10989-CTG Notice will be electronically mailed to:

Jacob A. Adlerstein on behalf of Interested Party Eli Lilly and Company

jadlerstein@paulweiss.com

Elihu Ezekiel Allinson, III on behalf

of Interested Party Shire Human Genetic Therapies, Inc.

ZAllinson@SHA-LLC.com, ecf@williamdsullivanllc.com; hcoleman@sha-llc.com

Olya Antle on behalf of Debtor Sangamo Therapeutics, Inc.

oantle@cooley.com, efilingnotice@cooley.com;efiling-notice@ecf.pacerpro.com

Joseph N. Argentina, Jr. on behalf of Creditor VWR International, LLC

joseph. argentina@faegredrinker.com, cathy.greer@faegredrinker.com

Darren Azman on behalf of Creditor Committee Official Committee of Unsecured Creditors of Sangamo Therapeutics, Inc. dazman@mcdermottlaw.com

Joshua Brooks on behalf of Interested Party PTC Therapeutics, Inc.

brooks@lrclaw.com, ramirez@lrclaw.com;huynh@lrclaw.com;hitchens@lrclaw.com;ford@lrclaw.com;kittinger@lrclaw.com

Kate R. Buck on behalf of Interested Party Astellas Gene Therapies, Inc.

kbuck@mccarter. com

Linda J. Casey on behalf of U.S. Trustee

U.S. Trustee

Linda.Casey@usdoj.gov

Austin Chavez on behalf

of Interested Party PTC Therapeutics, Inc.

austin.chavez@wilmerhale.com, Mike.McGuinness@wilmerhale.com

Shawn M. Christianson on behalf of Creditor Oracle America, Inc.

schristianson@buchalter.com, cmcintire@buchalter.com

James A.

Copeland on behalf of Interested Party Northridge ATM, LLC

james.copeland@nortonrosefulbright.com

Kristin Cunningham on behalf of Debtor Sangamo Therapeutics, Inc.

cunningham@rlf.com, rbgroup@rlf.com; rebecca--speaker-6328@ecf.pacerpro.com

Daniel J. DeFranceschi on behalf of Debtor Sangamo Therapeutics, Inc.

defranceschi@rlf.com, RBGroup@rlf.com;ann-jerominski-2390@ecf.pacerpro.com;rebecca--speaker-6328@ecf.pacerpro.com

Robert J. Dehney on behalf of Interested Party Eli Lilly and Company

rdehney@morrisnichols.com, robert-dehney-4464@ecf.pacerpro.com;jlawrence@morrisnichols.com;john-lawrence-

0804@ecf.pacerpro.com;rchevli@morrisnichols.com;radha--chevli--2257@ecf.pacerpro.com

Brenna Anne Dolphin on behalf of Interested Party Eli Lilly and Company

bdolphin@morrisnichols.com, brenna-dolphin-9491@ecf.pacerpro.com;john-lawrence-

0804@ecf.pacerpro.com;jlawrence@morrisnichols.com;rchevli@morrisnichols.com;radha--chevli--2257@ecf.pacerpro.com

Andrew C. Ehrmann on behalf of Interested Party Northridge ATM, LLC

EX-99.2

Filename: d179328dex992.htm · Sequence: 3

EX-99.2

Exhibit 99.2

UNITED STATES BANKRUPTCY COURT

DISTRICT OF DELAWARE

In Re. SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Debtor(s)

☐ Jointly Administered

Amended Monthly Operating Report

Chapter 11

Reporting Period Ended: 08/31/2026

Petition Date: 06/23/2026

Months Pending: 2

Industry Classification:

Reporting Method:

Accrual Basis

Cash Basis

Debtor’s Full-Time Employees (current):

Debtor’s Full-Time Employees (as of date of order for relief):

Supporting Documentation (check all that are attached):

(For jointly administered debtors, any required schedules must be provided on a non-consolidated basis for each debtor)

☒

Statement of cash receipts and disbursements

☒

Balance sheet containing the summary and detail of the assets, liabilities and equity (net worth) or deficit

☒

Statement of operations (profit or loss statement)

☐

Accounts receivable aging

☐

Postpetition liabilities aging

☐

Statement of capital assets

☐

Schedule of payments to professionals

☒

Schedule of payments to insiders

☒

All bank statements and bank reconciliations for the reporting period

☒

Description of the assets sold or transferred and the terms of the sale or transfer

/s/ Nikunj Jain

Nikunj Jain

Signature of Responsible Party

Printed Name of Responsible Party

10/23/2026

Date

501 Canal Blvd., Suite A100 Richmond, CA 94804

Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. §1320.4(a)(2) applies.

UST Form 11-MOR (12/01/2021)

Docket No. 538

Filed: 10/23/26

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Part 1: Cash Receipts and Disbursements

Current Month

Cumulative

Cash balance beginning of month

16,906,954

Total receipts (net of transfers between accounts)

10,145,433

38,707,494

Total disbursements (net of transfers between accounts)

3,826,691

20,338,902

Cash balance end of month (a+b-c)

23,225,696

Disbursements made by third party for the benefit of the estate

Total disbursements for quarterly fee calculation (c+e)

3,826,691

20,338,902

Part 2: Asset and Liability Status

(Not generally applicable to Individual Debtors. See Instructions.)

Current Month

Accounts receivable (total net of allowance)

90,355

Accounts receivable over 90 days outstanding (net of allowance)

90,355

Inventory (Book

Market

Other

(attach explanation))

Total current assets

25,398,606

Total assets

147,881,705

Postpetition payables (excluding taxes)

28,270,062

Postpetition payables past due (excluding taxes)

768,173

Postpetition taxes payable

308,160

Postpetition taxes past due

Total postpetition debt (f+h)

28,578,222

Prepetition secured debt

Prepetition priority debt

32,543

Prepetition unsecured debt

78,651,484

Total liabilities (debt) (j+k+l+m)

107,262,249

Ending equity/net worth (e-n)

40,619,456

Part 3: Assets Sold or Transferred

Current Month

Cumulative

Total cash sales price for assets sold/transferred outside the ordinary course of business

2,300,000

Total payments to third parties incident to assets being sold/transferred outside the ordinary course of business

Net cash proceeds from assets sold/transferred outside the ordinary course of business (a-b)

2,300,000

Part 4: Income Statement (Statement of Operations)

(Not generally applicable to Individual Debtors. See Instructions.)

Current Month

Cumulative

Gross income/sales (net of returns and allowances)

430,190

Cost of goods sold (inclusive of depreciation, if applicable)

Gross profit (a-b)

430,190

Selling expenses

General and administrative expenses

3,679,482

Other expenses

602,848

Depreciation and/or amortization (not included in 4b)

137,645

Interest

192,082

Taxes (local, state, and federal)

Reorganization items

9,979,799

Profit (loss)

-14,449,029

-29,369,386

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Part 5: Professional Fees and Expenses

Approved

Current Month

Approved

Cumulative

Paid Current

Month

Paid

Cumulative

Debtor’s professional fees & expenses (bankruptcy) Aggregate Total

$515,399

Itemized Breakdown by Firm

Firm Name

Role

Raymond James

Financial Professional

$175,000

Verita

Other

$340,399

iii

vii

viii

xii

xiii

xiv

xvi

xvii

xviii

xix

xxi

xxii

xxiii

xxiv

xxv

xxvi

xxvii

xxviii

xxix

xxx

xxxi

xxxii

xxxiii

xxxiv

xxxv

xxxvi

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

xxxvii

xxxviii

xxxix

xli

xlii

xliii

xliv

xlv

xlvi

xlvii

xlviii

xlix

lii

liii

liv

lvi

lvii

lviii

lix

lxi

lxii

lxiii

lxiv

lxv

lxvi

lxvii

lxviii

lxix

lxx

lxxi

lxxii

lxxiii

lxxiv

lxxv

lxxvi

lxxvii

lxxviii

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

lxxix

lxxx

lxxxi

lxxxii

lxxxiii

lxxxiv

lxxxv

lxxxvi

lxxxvii

lxxxviii

lxxxix

xci

xcii

xciii

xciv

xcv

xcvi

xcvii

xcviii

xcix

Approved

Current Month

Approved

Cumulative

Paid Current

Month

Paid

Cumulative

Debtor’s professional fees & expenses (nonbankruptcy) Aggregate Total

$11,851

$12,199

Itemized Breakdown by Firm

Firm Name

Role

Rothwell, Figg, Ernst & Manbec

Special Counsel

$11,693

$11,988

Daijogo & Pedersen, LLP

Special Counsel

$ 0

$ 53

iii

Kilpatrick Townsend & Stockto

Special Counsel

$ 158

vii

viii

xii

xiii

xiv

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

xvi

xvii

xviii

xix

xxi

xxii

xxiii

xxiv

xxv

xxvi

xxvii

xxviii

xxix

xxx

xxxi

xxxii

xxxiii

xxxiv

xxxv

xxxvi

xxxvii

xxxviii

xxxix

xli

xlii

xliii

xliv

xlv

xlvi

xlvii

xlviii

xlix

lii

liii

liv

lvi

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

lvii

lviii

lix

lxi

lxii

lxiii

lxiv

lxv

lxvi

lxvii

lxviii

lxix

lxx

lxxi

lxxii

lxxiii

lxxiv

lxxv

lxxvi

lxxvii

lxxviii

lxxix

lxxx

lxxxi

lxxxii

lxxxiii

lxxxiv

lxxxv

lxxxvi

lxxxvii

lxxxviii

lxxxix

xci

xcii

xciii

xciv

xcv

xcvi

xcvii

xcviii

xcix

c. All professional fees and expenses (debtor & committees)

$ 0

$527,250

$527,597

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Part 6: Postpetition Taxes

Current Month

Cumulative

a. Postpetition income taxes accrued (local, state, and federal)

b. Postpetition income taxes paid (local, state, and federal)

c. Postpetition employer payroll taxes accrued

211,413

493,588

d. Postpetition employer payroll taxes paid

455,499

877,333

e. Postpetition property taxes paid

361,948

f. Postpetition other taxes accrued (local, state, and federal)

96,747

154,151

g. Postpetition other taxes paid (local, state, and federal)

Part 7: Questionnaire - During this reporting period:

a. Were any payments made on prepetition debt? (if yes, see

Instructions)

Yes

b. Were any payments made outside the ordinary course of business without court

approval? (if yes, see Instructions)

Yes

c. Were any payments made to or on behalf of insiders?

Yes

d. Are you current on postpetition tax return filings?

Yes

e. Are you current on postpetition estimated tax payments?

Yes

f. Were all trust fund taxes remitted on a current basis?

Yes

g. Was there any postpetition borrowing, other than trade credit? (if yes, see

Instructions)

Yes

h. Were all payments made to or on behalf of professionals approved by the

court?

Yes

N/A

i. Do you have: Worker’s compensation insurance?

Yes

If yes, are your premiums current?

Yes

N/A

(if no, see Instructions)

Casualty/property insurance?

Yes

If yes, are your premiums current?

Yes

N/A

(if no, see Instructions)

General liability insurance?

Yes

If yes, are your premiums current?

Yes

N/A

(if no, see Instructions)

j. Has a plan of reorganization been filed with the court?

Yes

k. Has a disclosure statement been filed with the court?

Yes

l. Are you current with quarterly U.S. Trustee fees as set forth under 28

U.S.C. § 1930?

Yes

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Part 8: Individual Chapter 11 Debtors (Only)

a. Gross income (receipts) from salary and wages

$ 0

b. Gross income (receipts) from self-employment

$ 0

c. Gross income from all other sources

$ 0

d. Total income in the reporting period (a+b+c)

$ 0

e. Payroll deductions

$ 0

f. Self-employment related expenses

$ 0

g. Living expenses

$ 0

h. All other expenses

$ 0

i. Total expenses in the reporting period (e+f+g+h)

$ 0

j. Difference between total income and total expenses (d-i)

$ 0

k. List the total amount of all postpetition debts that are past due

$ 0

l. Are you required to pay any Domestic Support Obligations as defined by 11

U.S.C § 101(14A)?

Yes

m. If yes, have you made all Domestic Support Obligation payments?

Yes

N/A

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information, and provision of this information is mandatory under 11 U.S.C. §§ 704, 1106,

may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee’s systems of records notice,

UST-001, “Bankruptcy Case Files and Associated Records.” See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link:

I declare under penalty of perjury that the foregoing Monthly Operating Report and its supporting documentation are true and correct and that I

have been authorized to sign this report on behalf of the estate.

/s/ Nikunj Jain

Nikunj Jain

Signature of Responsible Party

Printed Name of Responsible Party

Interim Chief Financial Officer

10/23/2026

Title

Date

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Page One Part One Page One Part Two Page Two Part One Page Two Part Two

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Bankruptcy 1 to 50 Bankruptcy 51 to 100 Non Bankruptcy 1 to 50 Non Bankruptcy 51 to 100 UST Form

11-MOR (12/01/2021)

UST Form 11-MOR (12/01/2021)

Debtor’s Name SANGAMO THERAPEUTICS, INC.

Case No. 26-10989

Page Three Page Four

UST Form 11-MOR (12/01/2021)

IN THE UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT DELAWARE

)

In re:

)

Chapter 11

)

SANGAMO THERAPEUTICS, INC.

)

Case No. 26-10989 (CTG)

)

Debtor.1

)

GLOBAL NOTES AND STATEMENT OF LIMITATIONS, METHODOLOGY, AND DISCLAIMERS REGARDING THE DEBTOR’S

AMENDED2 MONTHLY OPERATING REPORT

On June 23, 2026

(the “Petition Date”), Sangamo Therapeutics, Inc. (the “Debtor”) commenced the above-captioned chapter 11 case by filing a voluntary petition for relief under chapter 11 of title 11 of the United States Code

(the “Bankruptcy Code”) with the United States Bankruptcy Court for the District of Delaware (the “Court”). The Debtor is authorized to operate its business as a debtor-in-possession pursuant to sections 1107(a) and 1108 of the Bankruptcy Code.

General

Methodology

The Debtor is filing its monthly operating report (the “MOR”) for the period from August 1,

2026 through August 31, 2026 (the “Reporting Period”) for purposes of complying with the monthly reporting requirements applicable in the Debtor’s chapter 11 case. The MOR is unaudited and has not been prepared in

accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and does not include all of the information and footnotes required by U.S. GAAP. The MOR is not intended to reconcile to any

financial statements otherwise prepared or distributed by the Debtor. The MOR should not be relied upon by any persons for information relating to current or future financial condition, events, or performance of the Debtor or its affiliates, as the

results of operations contained herein are not necessarily indicative of results which may be expected from any other period or for the full year and may not necessarily reflect the results of operations, financial position, and schedule of receipts

and disbursements in the future.

The Debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc.

(9556). The Debtor’s mailing address is 7000 Marina Blvd, Brisbane, CA 94005.

This amended monthly operating report amends the August monthly operating report filed at Docket No. 513

to add information regarding payments inadvertently made to ordinary course professionals, as set forth in part 5(b) of the monthly operating report form and the attached attestation titled “Part 7(b) and 7(h) Payments Without Court

Approval.”

Basis for Presentation

In preparing the MOR, the Debtor relied on financial information from its books and records at the time of such preparation. The financial

This information has not been subjected to procedures that would typically be applied to financial information presented in accordance with

Although the Debtor made efforts to ensure the accuracy and completeness of the MOR, given the complexity of the Debtor’s business,

in the MOR. Further, the Debtor reserves the right to amend or supplement the MOR, if necessary, but shall be under no obligation to do so.

Moreover, given, among other things, the uncertainty surrounding the valuation and ownership of certain assets and the valuation and nature of

liabilities than assets, it is not an admission that the Debtor was insolvent at the Petition Date or any time prior to the Petition Date.

For the reasons discussed above, there can be no assurance that the financial information presented in the MOR is complete, and readers are

strongly cautioned not to place undue reliance on the MOR.

Each signatory to the MOR has necessarily relied upon the efforts, statements,

the MOR.

Reporting Period

Unless otherwise noted herein, the MOR generally reflects the Debtor’s books and records for the applicable Reporting Period. Unless

otherwise noted herein, no adjustments have been made for activity occurring after the close of the Reporting Period.

Accuracy

The financial information disclosed in the MOR was not prepared in accordance with federal or state securities laws or other

laws in the MOR or for any evaluations of the Debtor, including of their financial condition, based on this financial information or any other information.

Debtor in Possession Financing

On June 25, 2026, the Court entered the Interim Order (A) Authorizing the Debtor to Obtain Postpetition Financing,

(B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief

[Docket No. 63] (the “Initial Interim DIP Order”) authorizing the Debtor to enter into a senior secured superpriority debtor-in-possession

Order for additional information regarding the Initial DIP Facility.

On July 23, 2026, the Court entered the Interim Order

(A) Authorizing the Debtor to Obtain Replacement Postpetition Financing, (B) Granting Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay,

(D) Scheduling Final Hearing, and (E) Granting Related Relief [Docket No. 176] (the “Replacement Interim DIP Order”), which, among other things, authorized the Debtor to enter into a senior

secured superpriority debtor-in possession term loan facility (the “Replacement DIP Facility”) with Future Solution Investments LLC (“FSI”), as lender, to replace the

Initial DIP Facility. Prior to the Reporting Period, the Debtor incurred $18 million in DIP Obligations (as defined in the Replacement DIP Order) under the Replacement DIP Facility, $11,432,958 of which was paid by the Debtor or on the

Debtor’s behalf to satisfy all outstanding obligations arising under the Initial DIP Facility, including all fees. Please refer to the motion [Docket No. 161] (the “Replacement DIP Motion”) seeking entry of the

Replacement Interim DIP Order for additional information regarding the Replacement DIP Facility.

On August 20, 2026, the Court

entered an order [Docket No. 360] (the “Replacement Final DIP Order,” and together with the Initial Interim DIP Order and the Replacement Interim DIP Order, the “DIP Orders”) granting the relief requested

in the Replacement DIP Motion on a final basis. The Final Replacement DIP Order authorized the Debtor to borrow up to $35 million under the Replacement DIP Facility ($17 million more than was authorized by the Replacement Interim DIP

Order). During the Reporting Period, (i) the Debtor drew $7 million in additional DIP Obligations under the Replacement Final DIP Order, and (ii) FSI credit bid $250,000 of DIP Obligations in connection with the FSI Equipment Sale (as

defined below).

Payment of Prepetition Claims Pursuant to First Day Orders

Pursuant to certain interim orders of the Court entered on or about June 24, 2026 and final orders of the Court entered on or about

have been included in the MOR (subject to the notes and statements and limitations provided herein).

Reservation of Rights

The Debtor reserves all rights to amend or supplement the MOR in all respects, as may be necessary or appropriate. Nothing contained in the

MOR shall constitute a waiver of any of the Debtor’s rights or an admission with respect to any claim against the Debtor or otherwise in connection with this chapter 11 case.

Specific MOR Disclosures

Part

1: Cash Receipts and Disbursements

Pursuant to the DIP Orders, fees and expenses of estate professionals were placed into the Professional Fees

Account (as defined in the DIP Orders) maintained by the Debtor. The transfer of such funds to the Professional Fee Account were treated as a transfer between Debtor accounts, and, therefore, were not treated as a distribution in Part 1(c).

Professional fees will be treated as a disbursement in the reporting period in which they are paid to the applicable professionals.

Similarly, pursuant

to the interim and final orders approving, among other things, the Debtor’s proposed form of adequate assurance of payment to utility companies [Docket Nos. 56 & 142] (the “Utilities Orders”), the Debtor deposited funds

into the Utility Deposit Account (as defined in the Utilities Orders) prior to the Reporting Period. The Utility Deposit Account is a segregated account maintained by the Debtor. Accordingly, the funds in such account will be treated as

disbursements only if they are ultimately paid to a third party.

Notes to Part 2: Asset and Liability Status

Unless otherwise noted, all asset and liability information included in the MOR reflects net book value, which may differ from current market value. As set

forth above, this information has not been subjected to procedures that would typically be applied to financial information presented in accordance with U.S. GAAP or any other recognized financial reporting framework. If such procedures were

applied, the Debtor believes that the financial information presented in the MOR could be subject to change, including material change. Asset and liability information includes intercompany claims and other assets and liabilities which may not be

settled in cash.

The Debtor continues to pay postpetition invoices on account of postpetition goods provided and services rendered in the ordinary course

of business.

Given the Petition Date did not occur at month end, certain prepetition and postpetition liability balances are estimated. The Debtor has

sought to assign liabilities to the prepetition and postpetition periods based on the information available as of and at the time the MOR was prepared. As additional information becomes available, the allocation of liabilities between prepetition

and postpetition periods may change. The Debtor reserves the right to amend the balances as it deems appropriate and any such amendments will be reflected in future MORs.

The amounts listed as “Prepetition Secured Debt,” “Prepetition Priority Debt” and

“Prepetition Unsecured Debt” are preliminary and are subject to ongoing review and reconciliation by the Debtor. All amounts and classifications are subject to material adjustments.

Regarding Part 2c, the Debtor does not hold inventory; therefore, no inventory valuation method is applicable.

Note to Part 3: Assets Sold or Transferred

August 20, 2026, the Court entered: (i) an order [Docket No. 356] approving the sale (the “Surplus Equipment Sale”) of certain equipment and office furniture to Surplus Solutions, LLC for $2,300,000 plus certain

other consideration, and (ii) an order [Docket No. 358] approving the sale (the “FSI Equipment Sale,” and together with the Surplus Equipment Sale, the “Equipment Sales”) of certain lab equipment to

FSI for an offset of $250,000 against the DIP Obligations (as defined in the Replacement Final DIP Order) plus certain other consideration. Both equipment sales closed on or about August 20, 2026.

Notes to Part 5: Professional Fees and Expenses

All

payments to professionals were authorized by the Court’s orders approving the retention of various professionals in this Chapter 11 Case. For the Reporting Period, such amounts represent: (i) fees paid to Kurtzman Carson Consultants, LLC dba

Verita Global for services performed and expenses incurred in connection with its retention as claims and noticing agent (see Docket No. 55), and (ii) a monthly fee payable to Raymond James & Associates, Inc., which is

payable each month without a prior fee application (see Docket No. 276).

Notes to Part 6: Postpetition Taxes

Regarding Part 6c and 6d, postpetition employer payroll taxes accrued and paid include both the employer and employee portions of payroll taxes.

Notes to Part 7: Questionnaire

Please see attached

attestations regarding post-petition borrowing, payments on prepetition debt, and payments to insiders.

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.

Case No: 26-10989

Schedule of Post-Petition Borrowing Activity

Reporting Period: August 1, 2026 – August 31, 2026

The Debtor hereby submits this attestation regarding postpetition borrowing during the period of August 1, 2026 through August 31, 2026.

Pursuant to the Final Order (A) Authorizing the Debtor to Obtain Replacement Postpetition Financing, (B) Granting

Liens and Providing Claims with Superpriority Administrative Expense Status, (C) Modifying Automatic Stay, (D) Scheduling Final Hearing, and (E) Granting Related Relief

[Docket No. 360] (the “Replacement Final DIP Order”) during the reporting period: (i) the Debtor incurred $7 million in DIP Obligations under the Replacement DIP Facility (each as defined in the Replacement

Final DIP Order), and (ii) FSI credit bid $250,000 of DIP Obligations in connection with the FSI Equipment Sale.

/s/ Nikunj Jain

October 23, 2026

Signature of Authorized Individual

Date

Nikunj Jain

Interim Chief Financial Officer

Printed Name of Authorized Individual

Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.

Case No: 26-10989

Schedule of Payments on Prepetition Debt

Reporting Period: August 1, 2026 – August 31, 2026

All payments made by the Debtor during the Reporting Period (and included in the disbursements reported in this MOR) were authorized under various final

orders granted by the Court, which authorized the Debtor’s various motions that were filed following the commencement of the chapter 11 case.

/s/ Nikunj Jain

October 23, 2026

Signature of Authorized Individual

Date

Nikunj Jain

Interim Chief Financial Officer

Printed Name of Authorized Individual

Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.

Case No: 26-10989

Part 7(b) and 7(h) Payments Without Court Approval

Reporting Period: July 1, 2026 – July 31, 2026

Payments made by the Debtor to Rothwell, Figg, Ernst & Manbeck, P.C. and Kilpatrick Townsend & Stockton LLP were inadvertently made prior to

such firm’s retention as ordinary course professionals in accordance with the OCP Order [Docket No. 202].

/s/ Nikunj Jain

October 23, 2026

Signature of Authorized Individual

Date

Nikunj Jain

Interim Chief Financial Officer

Printed Name of Authorized Individual

Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.

Case No: 26-10989

Schedule of Payments to Insiders

Reporting Period: August 1, 2026 – August 31, 2026

The Debtor hereby submits this attestation regarding payments to insiders during the period of August 1, 2026 through August 31, 2026.

With respect to insiders, all cash payments made were on account of ordinary course salaries and authorized travel and expense reimbursements.

On July 31, 2026, the Court entered an order [Docket No. 216], among other things, authorizing the Debtor to implement a key employee retention

program and a key employee incentive program (the “KEIP/KERP Programs”). No payments were made under the KEIP/KERP Programs to insiders or otherwise during the Reporting Period.

As set forth in the Debtor’s motion seeking authority to pay prepetition employee obligations [Docket No. 9], the Debtor maintained certain

equity-based compensation programs prior to the Petition Date. Pursuant to such programs, certain employees, including certain executives that may be insiders, were awarded restricted stock units (the “RSUs”) prior to the Petition

Date. During the Reporting Period, 213,628 RSUs awarded to 74 individuals prior to the Petition Date vested. For the avoidance of doubt, the Debtor stopped awarding RSUs prior to the Petition Date and no RSUs or any other form of equity-based

compensation have been awarded since the Petition Date.

No other non-cash transfers were made during this

reporting period.

/s/ Nikunj Jain

October 23, 2026

Signature of Authorized Individual

Date

Nikunj Jain

Interim Chief Financial Officer

Printed Name of Authorized Individual

Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.

Case No: 26-10989

All bank statements and bank reconciliations for the reporting period

Reporting Period: August 1, 2026 – August 31, 2026

The Debtor hereby submits this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations, and

journal entries.

The Debtor’s standard practice is to ensure that bank reconciliations are completed as part of the month end close each reporting

period. I attest that each of the Debtor’s bank accounts has been reconciled in accordance with its standard practices.

/s/ Nikunj Jain

October 23, 2026

Signature of Authorized Individual

Date

Nikunj Jain

Interim Chief Financial Officer

Printed Name of Authorized Individual

Title of Authorized Individual

UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE

Sangamo Therapeutics, Inc.

Case No: 26-10989

Assets Sold or Transferred

Reporting Period: August 1, 2026 – August 31, 2026

The Debtor hereby submits this attestation regarding assets sold or transferred during the period of August 1, 2026 through August 31, 2026.

On August 20, 2026, the Court entered: (i) an order [Docket No. 356] approving the sale (the “Surplus Equipment Sale”) of

certain equipment and office furniture to Surplus Solutions, LLC for $2,300,000 plus certain other consideration, and (ii) an order [Docket No. 358] approving the sale (the “FSI Equipment Sale,” and together with the

Surplus Equipment Sales, the “Equipment Sales”) of certain lab equipment to FSI for an offset of $250,000 against the DIP Obligations (as defined in the Replacement Final DIP Order) plus certain other consideration. Both equipment

sales closed on or about August 20, 2026.

/s/ Nikunj Jain

October 23, 2026

Signature of Authorized Individual

Date

Nikunj Jain

Interim Chief Financial Officer

Printed Name of Authorized Individual

Title of Authorized Individual

Sangamo Therapeutics Inc.

MOR #3 - Statement of cash receipts and

disbursements

$ in 000s

07/01/2026 -

07/31/2026

08/01/2026 -

08/31/2026

Receipts

3,145

DIP Draw

18,000

7,000

Total Receipts

18,059

10,145

Operational Disbursements

Payroll & Benefits

1,747

1,693

Rent & Facilities

1,348

319

Program Costs

319

226

International Operations

416

240

Other Operating Disbursements

271

579

Total Operational Disbursements

4,101

3,057

Restructuring Disbursements

Professional Fees

—

515

US Trustee Fees

—

DIP Interest & Fees

933

250

DIP Repayments

10,500

—

Total Restructuring Disbursements

11,433

769

Net Cash Flow

2,525

6,319

Cash, cash equivalents, and restricted cash, beginning of period

14,382

16,907

Cash, cash equivalents, and restricted cash, end of period

16,907

23,226

1 of 4

Sangamo Therapeutics Inc.

MOR #3 - Balance sheet

$ in 000s

As of

07/31/2026

08/31/2026

Assets

Cash, Cash Equivalents and Restricted Cash

16,910

23,197

Accounts Receivables

500

Other Current Assets

2,977

2,111

Total Current Assets

20,387

25,399

Property, Plant & Equipment (Net)

9,430

Right of Use Assets3

2,694

—

Other Non-Current Assets

779

613

Investments in Subsidiaries

115,762

I/C Receivables - Non-Current

6,067

6,106

Total Non-Current Assets

134,731

122,483

Total Assets

155,118

147,882

Liabilities and Stockholders’ Equity

A/P and Accrued Liabilities

36,735

44,182

Compensation and Benefits Liabilities

17,304

17,397

DIP Loan Payables2

18,000

24,942

Other Current Liabilities1

8,713

9,723

I/C Payables - Current

42,687

42,903

Other Non-Current Liabilities1

23,240

14,754

I/C Payables - Non-Current

703

708

Total Liabilities

147,383

154,609

Stock

1,643,342

1,643,328

Retained Earnings

(1,564,836

)

(1,564,836

)

Other Equity

(30

)

(30

)

Net Income

(70,741

)

(85,190

)

Total Stockholders’ Equity

7,735

6,727

)

Total Liabilities and Stockholders’ Equity

155,118

147,882

Notes:

Includes:

Deferred Revenues

Lease Liabilities; the Richmond lease is presented as a one-year

liability, estimated for lease rejection purposes

Includes accrued August DIP interest of $192K (paid 9/2); net of FSI’s $250K lab equipment credit bid

Fully written off in August in connection with the wind-down of Richmond facility

2 of 4

Sangamo Therapeutics Inc.

MOR #3 - Statement of operations

(profit or loss statement)

$ in 000s

07/01/2026 -

07/31/2026

08/01/2026 -

08/31/2026

Total Revenue

720

430

COGS

—

Gross Profit

720

430

Personnel & Staffing Costs1

1,931

1,693

R&D Expenses2

3,184

473

Selling Expenses

—

General and Administrative Expenses4

863

1,037

Facilities & OH Expenses1

972

950

I/C Expenses2

127

Other Expenses2

Interest Expense

105

192

Restructuring Expenses3

4,244

9,980

Depreciation and/or amortization

216

138

Total Operating Expenses

11,562

14,592

Unrealized FX (Gain)/Loss

336

292

Non-Operating (Income)/Expense

(12

)

Total Non-Operating (Income)/Expense

323

287

Net Profit/(Loss) for the Period

11,165

)

14,449

)

Notes:

Considered under “General and Administrative Expenses” for MOR

Considered under “Other Expenses” for MOR

Includes professional fees and asset write-offs/disposals, net of lease rejection gains

Includes D&O insurance expense for prior months not previously recognized, recorded in August

3 of 4

Sangamo Therapeutics Inc.

MOR #3 - Detailed explanations

Part 2 - Question C - Inventory

Sangamo does not hold

inventory; therefore, no inventory valuation method is applicable

Part 7 - Question G - Was there any postpetition borrowing, other than trade credit?

Detail

Date

Payee/Lender Name

Amount

DIP draw

8/21/2026

Future Solution Investments LLC

7,000,000

4 of 4

Miscellaneous:

26-10989-CTG Sangamo Therapeutics, Inc.

Type: bk

Chapter: 11 v

Office: 1 (Delaware)

Assets: y

Judge: CTG

Case Flag: CLMSAGNT, LeadSC, PlnDue, DsclsDue, STANDOrder, SealedDoc(s)

U.S. Bankruptcy Court

District of Delaware

Notice of

Electronic Filing

The following transaction was received from James McCauley entered on 10/23/2026 at 1:03 PM EDT and filed on 10/23/2026

Case Name:

Sangamo Therapeutics, Inc.

Case Number:

26-10989-CTG

Document Number:

538

Docket Text:

Amended

Chapter 11 Monthly Operating Report for the Month Ending: 08/31/2026 (related document(s)[513]) Filed by Sangamo Therapeutics, Inc.. (McCauley, James)

The

following document(s) are associated with this transaction:

Document description:Main Document

Original filename:SGMO - August 2026 MOR [AMENDED].pdf

Electronic document Stamp:

[STAMP bkecfStamp_ID=983460418

[Date=10/23/2026] [FileNumber=20049567- 0][69bdb41297fe57581063fc1b02a27c05cfe148b80b016323f14884f454e676452d

c3558b420144fafd3a3b88f7bf8f2480d23e562f046a964696f82bb68edf46]]

26-10989-CTG Notice will be electronically mailed to:

Jacob A. Adlerstein on behalf of Interested Party Eli Lilly and Company

jadlerstein@paulweiss.com

Elihu Ezekiel Allinson, III on behalf

of Interested Party Shire Human Genetic Therapies, Inc.

ZAllinson@SHA-LLC.com,

ecf@williamdsullivanllc.com;hcoleman@sha-llc.com

Olya Antle on behalf of Debtor Sangamo Therapeutics, Inc.

oantle@cooley.com, efilingnotice@cooley.com;efiling-notice@ecf.pacerpro.com

Joseph N. Argentina, Jr. on behalf of Creditor VWR International, LLC

joseph.argentina@faegredrinker.com, cathy.greer@faegredrinker.com

Darren Azman on behalf of Creditor Committee Official Committee of Unsecured Creditors of Sangamo Therapeutics, Inc.

dazman@mcdermottlaw.com

Joshua Brooks on behalf of Interested

Party PTC Therapeutics, Inc.

brooks@lrclaw.com, ramirez@lrclaw.com;huynh@lrclaw.com;hitchens@lrclaw.com;ford@lrclaw.com;kittinger@lrclaw.com

Kate R. Buck on behalf of Interested Party Astellas Gene Therapies, Inc.

kbuck@mccarter.com

Linda J. Casey on behalf of U.S. Trustee U.S.

Trustee

Linda.Casey@usdoj.gov

Austin Chavez on behalf of

Interested Party PTC Therapeutics, Inc.

austin.chavez@wilmerhale.com, Mike.McGuinness@wilmerhale.com

Shawn M. Christianson on behalf of Creditor Oracle America, Inc.

schristianson@buchalter.com, cmcintire@buchalter.com

James A.

Copeland on behalf of Interested Party Northridge ATM, LLC

james.copeland@nortonrosefulbright.com

Kristin Cunningham on behalf of Debtor Sangamo Therapeutics, Inc.

cunningham@rlf.com, rbgroup@rlf.com;rebecca--speaker-6328@ecf.pacerpro.com